IP Verse

Azurity Pharmaceuticals, Inc. V. Novitium Pharma, Llc - 1:23-cv-00163

Explore the details of the Azurity Pharmaceuticals, Inc. V. Novitium Pharma, Llc case under case number 1:23-cv-00163 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00163
Filing Date
Feb 14, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent

Parties Involved in the Case

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Bionpharma Inc. -
Novitium Pharma LLC -
Azurity Pharmaceuticals, Inc. -

Patents Involved in the Case

This case involves 2 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US11141405B2
-US11040023B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Dec 1, 2022LETTER ORDER granting Plaintiff's 36 Letter request to unseal the Opposition at docket entry 26 . Signed by Magistrate Judge Edward S. Kiel on 12/1/2022. (mxw) [Transferred from New Jersey on 2/14/2023.] (Entered: 12/02/2022)PACER Document
Dec 13, 2022Letter from Kathleen N. Fennelly, Esq., Attaching Order Staying Discovery in Delaware Third Wave Suits. (FENNELLY, KATHLEEN) [Transferred from New Jersey on 2/14/2023.] (Entered: 12/13/2022)PACER Document
Jan 4, 2023TEXT ORDER: The Court is in receipt of Plaintiff's letter dated December 12, 2022, informing the Court of an unrelated relationship the Undersigned has with a family member of one of Plaintiff's counsel in a different case. The Court is also in receipt of Defendant's and Proposed Intervenor Defendant's December 28, 2022 email notifying the Court that they do not believe that the purported relationship identified in Plaintiff's December 12 letter poses a conflict of interest for the Court, or anything warranting disqualification. In addition, the Court does not perceive of any conflict of interest warranting disqualification. See 28 U.S.C. §§ 144 and 455; see also Model Code of Judicial Conduct. Accordingly, the Undersigned intends to proceed with the present case. The Undersigned thanks the parties for their attention to this matter. So Ordered by Judge Esther Salas on 1/4/2023. (ek) [Transferred from New Jersey on 2/14/2023.] (Entered: 01/04/2023)PACER Document
Jan 20, 2023OPINION AND ORDER granting 10 Motion to Transfer Case to United States District Court for the District of Delaware; Administratively terminating 8 Motion to Intervene; CIVIL CASE TERMINATED. Signed by Magistrate Judge Edward S. Kiel on 1/20/2023. (mxw) Modified on 1/23/2023 (mxw, ). [Transferred from New Jersey on 2/14/2023.] (Entered: 01/23/2023)PACER Document
Feb 15, 2023Case Assigned to Judge Mitchell S. Goldberg of the United States District Court for the Eastern District of Pennsylvania, due to related cases (see 21-cv-1707, et al). Please include the initials of the Judge (MSG) after the case number on all documents filed. (rjb)PACER Document
Feb 16, 2023NOTICE: A status conference, on the record, is scheduled for February 28, 2023 at 11:00 a.m. The conference will be conducted via telephone. Counsel are directed to dial in as follows: (1) Call: 888-684-8852; (2) Enter access code: 2187450#; (3) Press # to enter as a participant. (apk) (Entered: 02/16/2023)PACER Document
Feb 24, 2023Pro Hac Vice Attorney Andrew M. Alul, Luke T. Shannon, and Roshan P. Shrestha for Novitium Pharma LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)PACER Document
Feb 28, 2023Pro Hac Vice Attorney Aaron M. Johnson for Novitium Pharma LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)PACER Document
Feb 28, 2023Minute Entry for proceedings held before Judge Mitchell S. Goldberg - Status Teleconference held on 2/28/2023. (twk)PACER Document
Mar 27, 2023Case associated with lead case: 1:21-cv-01286-MSG. All docketing should be done in the LEAD CASE ONLY. Associated Cases: 1:21-cv-01455-MSG, 1:23-cv-00163-MSG(smg)PACER Document
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Oct 3, 2022COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)Attachment
Apr 8, 2024ORDER: All claims against Novitium Pharma LLC having been dismissed by stipulation (Doc. No. 436 in 21-cv-1286), it is hereby ORDERED that the Clerk of Court shall mark Case 23-cv-163 as closed. (CASE CLOSED) Signed by Judge Mitchell S. Goldberg on 4/8/2024. (mpb) (Entered: 04/08/2024)PACER Document
Apr 8, 2024FINAL Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,040,023; 11,141,405. (mpb) (Entered: 04/08/2024)PACER Document